Besifloxacin - Ajanta Pharma

Drug Profile

Besifloxacin - Ajanta Pharma

Alternative Names: Besix

Latest Information Update: 17 Feb 2014

Price : $50

At a glance

  • Originator Ajanta Pharma
  • Class Antibacterials; Azepines; Carboxylic acids; Cyclopropanes; Fluoroquinolones; Small molecules
  • Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Infectious conjunctivitis

Most Recent Events

  • 12 Jul 2013 Launched for Infectious conjunctivitis in India (Ophthalmic) prior to July 2013
  • 04 Sep 2010 Ajanta Pharma completes a phase III trial in Infectious conjunctivitis in India
  • 11 Aug 2010 Ajanta Pharma completes enrolment in its phase III trial for Infectious conjunctivitis in India
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top